Another Astellas Gene Therapy Deal, This Time $50M for Option on AviadoBio Dementia Program

Another Astellas Gene Therapy Deal, This Time $50M for Option on AviadoBio Dementia Program

ACQG Enterprises Inc

The medical field is undergoing a rapid transformation, with exciting breakthroughs in treatments, technology, and patient care. From revolutionary gene therapies to AI-driven diagnostics, the future of medicine is full …

Related tracks